

Figure 1














A**B****C****D****E**

Figure 2

A**B****C****D****E****F****G****H**









A**B****C**

Figure 4


A**B**

A**B**

Supplementary Figure 1: FACS analysis of TRAIL receptor after chemotherapy Example of one representative analysis of TRAIL receptor expression in (A) control HeLa cells (H-Ct) (B) H-TRAIL-R4 cells, 48 hours (CDDP and VP16) or 72 hours (5FU) after chemotherapy. Untreated cells (white), stimulated with CDDP (grey), VP16 (dashed) or 5FU (black).



Supplementary Figure 2: Comparison of treatments schemes, sequential versus simultaneous combined TRAIL and 5FU. HCT116 cells deficient for Bax expression (grey bars) or Bax-deficient cells ectopically expressing TRAIL-R4 (black bars) were stimulated with 500 ng recombinant His-TRAIL, 1 µg/ml or 3.125 µg/ml 5FU for 72 hours or the combinations for 24 hours at the indicated concentrations, either sequentially (Seq) or simultaneously (Sim). Apoptosis was determined by Hoescht staining 24 h after TRAIL stimulation.



Supplementary Figure 3: The Pancaspase inhibitor zVAD but not the Caspase-9 inhibitor zLEHD abrogates chemotherapy-induced sensitization to TRAIL. After chemotherapy, parental H-TRAIL-R4 cells were pretreated for 30 minutes, prior His-TRAIL stimulation (500 ng/ml, 6 hours) with 25 μ M of z-VAD-fmk, 25 μ M z-LEHD-fmk or the corresponding amount of DMSO. Apoptosis was measured by Hoechst staining. These results are representative of 3 independent experiments. Mean apoptosis values and SD are shown (mean \pm SD).